All News
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.
Eric Dein ejdein1 ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Do you increase spacing of TNF-i administration in your patients with axSpA with sustained low disease activity for one year? OP0138 results showed similar relapse rates in those with increased spacing intervals and those on standard dosing regimen. #EULAR2021 @RheumNowNews
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 OP0138 - Radiographic AxSpA in LDA, SPACING anti-TNF vs continue care. 83% were able to ⬆️ dosing interval at month 12, drug efficacy recovered in pts with relapsed disease. Worth trying in stable patient who wants to wean down meds. @RheumNow
Eric Dein ejdein1 ( View Tweet)
Do patients with #SpA have a different phenotype if they have "root joint disease"?
Find out at the #EULAR2021 Poster Tour #POS0239
or at https://t.co/30JdHxTKus https://t.co/ocEefm8II9
Nelly ZIADE 🍀 Nellziade ( View Tweet)
@MeralElRamahiMD @RheumNow True that axSpA is diff from pts with peripheral SpA predominantly but isn’t it circular reasoning to say axial has more HLAB27+ as that is group in whom criteria were developed including HLAB27?
Janet Pope Janetbirdope ( View Tweet)
Don’t forget to use imaging that you already have!
CT Abd/Pelvis (ordered for nonMSK) of 301 IBD pts shows underlying sacroilitis
⭐️60/301 had sacroilitis on CT
⭐️11/60 had AxSpA
⭐️3/60 previously undiagnosed axSpA
Abs#POS0035
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi
➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l
#EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus
⭐️⬇️AS activity w/ or w/o MRI sacroilitis
Abs#OP0142
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of disease; xrays are not sensitive to pick up changes. While we're at it, can we just use the term "imaging" instead of "radiographs" with the availability of better tech? https://t.co/I6reoHyywf
k dao KDAO2011 ( View Tweet)
Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks!
⭐️Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes
⭐️no significant changes in spine fat, bone erosion or new bone formation
Abs#OP0141
#EULAR2021 @RheumNow https://t.co/tcBFuxnu4n
Robert B Chao, MD doctorRBC ( View Tweet)
Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disease! Abs#OP6875 #EULAR2021 @RheumNow
How do you help pts manage fatigue?
Robert B Chao, MD doctorRBC ( View Tweet)
➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID.
➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz
OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study?
⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID
⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w
🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA.
OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Interesting results from our post hoc analysis of #ASAS #PerSpA presented at #EULAR2021 by Dafne Capelusnik
⭐️Individual socioeconomic factors associated with poorer outcomes
⭐️Living in low GDP country associated with higher disease activity but paradoxically lower fatigue https://t.co/2SmKZPy8mw
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2021 PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting.
https://t.co/sUXTXDXrFh https://t.co/tQZktnlUXj
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021.
“SpA” talk by Prof. Désirée van der Heijde.
Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏
/TK https://t.co/JFr3VC8sXY
ARD & RMD Open ARD_BMJ ( View Tweet)
PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate)
https://t.co/sUXTXDXrFh
Dr. John Cush RheumNow ( View Tweet)
